Chemclin Diagnostics Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Chemclin Diagnostics Co., Ltd. carries a market capitalization of 2.46B, placing it among publicly traded companies globally. Its enterprise value stands at 2.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.46B |
| Enterprise Value | 2.08B |
Share Statistics
Chemclin Diagnostics Co., Ltd. currently has 401.11M shares outstanding.
| Shares Outstanding | 401.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Chemclin Diagnostics Co., Ltd. trades at a trailing price-to-earnings ratio of 35.79. The price-to-sales ratio is 7.13, and the price-to-book ratio stands at 3.26.
| PE Ratio | 35.79 |
| PS Ratio | 7.13 |
| PB Ratio | 3.26 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | 33.80 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Chemclin Diagnostics Co., Ltd. trades at an EV/EBITDA multiple of 27.96 and an EV/FCF ratio of 24.16. The EV/Sales ratio of 5.54 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.96 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.54 |
| EV / EBITDA | 27.96 |
| EV / EBIT | 27.96 |
| EV / FCF | 24.16 |
Financial Position
Chemclin Diagnostics Co., Ltd. maintains a current ratio of 7.10, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.59, indicating elevated leverage, while an interest coverage ratio of 9.87 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 7.10 |
| Quick Ratio | 5.96 |
| Debt / Equity | 18.59 |
| Debt / EBITDA | 3.48 |
| Interest Coverage | 9.87 |
Financial Efficiency
Chemclin Diagnostics Co., Ltd. posts a return on equity of 9.24 and a return on invested capital of 4.18.
| Return on Equity (ROE) | 9.24 |
| Return on Assets (ROA) | 4.18 |
| Return on Invested Capital (ROIC) | 4.18 |
| Return on Capital Employed (ROCE) | 7.67 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.00 |
Taxes
Over the trailing twelve months, Chemclin Diagnostics Co., Ltd. has paid 6.29M in income taxes, reflecting an effective tax rate of 7.75.
| Income Tax | 6.29M |
| Effective Tax Rate | 7.75 |
Stock Price Statistics
Chemclin Diagnostics Co., Ltd.'s stock has declined approximately -17.16216% over the past 52 weeks. The 50-day moving average sits at 6.68, while the 200-day moving average is 7.44.
| Beta (5Y) | N/A |
| 52-Week Price Change | -17.16216% |
| 50-Day Moving Average | 6.68 |
| 200-Day Moving Average | 7.44 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chemclin Diagnostics Co., Ltd. generated 375.32M in revenue and converted that into 74.77M in net income, yielding earnings per share of 0.21. EBITDA reached 74.41M, while operating income came in at 74.41M.
| Revenue | 375.32M |
| Gross Profit | 263.21M |
| Operating Income | 74.41M |
| Pretax Income | 81.06M |
| Net Income | 74.77M |
| EBITDA | 74.41M |
| EBIT | 74.41M |
| Earnings Per Share (EPS) | 0.21 |
Balance Sheet
Chemclin Diagnostics Co., Ltd. holds 853.65M in cash and equivalents against 258.63M in total debt, resulting in a net debt position of -278.46M. Total book value stands at 821.66M, with working capital of 873.48M providing operational flexibility.
| Cash & Cash Equivalents | 853.65M |
| Total Debt | 258.63M |
| Net Debt | -278.46M |
| Equity (Book Value) | 821.66M |
| Book Value Per Share | 2.26 |
| Working Capital | 873.48M |
Cash Flow
After subtracting -79.18M in capital expenditures, free cash flow totaled -79.18M - equivalent to -0.22 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -79.18M |
| Free Cash Flow | -79.18M |
| FCF Per Share | -0.22 |
Margins
Chemclin Diagnostics Co., Ltd. operates with a gross margin of 70.13, reflecting its pricing power and cost economics. The operating margin of 19.83 and net profit margin of 19.92 provide insight into operational efficiency.
| Gross Margin | 70.13 |
| Operating Margin | 19.83 |
| Pretax Margin | 21.60 |
| Profit Margin | 19.92 |
| EBITDA Margin | 19.83 |
Dividends & Yields
The company's payout ratio of 75.10 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.15 |
| Dividend Yield | N/A |
| Payout Ratio | 75.10 |
| Shareholder Yield | 2.36 |
| FCF Yield | 2.96 |
Scores
Chemclin Diagnostics Co., Ltd. posts an Altman Z-Score of 5.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.65 |